PORTFOLIO NEWS NGM Bio Provides Business Highlights and Reports First Quarter 2021 Financial Results May 6, 2021 Read More » ORIC Pharmaceuticals Reports First Quarter 2021 Financial Results and Operational Update May 6, 2021 Read More » ‘Changing the whole game of drug discovery’: Legendary R&D vet Roger Perlmutter leaps back into work as a biotech CEO May 5, 2021 Read More » Eikon Therapeutics Closes $148 Million Series A Financing to Develop High-Throughput, Super-Resolution Microscopy for Drug Discovery May 5, 2021 Read More » Perlmutter named CEO of Eikon, a biotech with $148M to apply Nobel-winning tech to undruggable targets May 5, 2021 Read More » Carmot Therapeutics Announces Investigational New Drug (IND) Clearance for CT-868, a Dual GLP-1 and GIP Receptor Modulator for the Treatment of Overweight and Obese Patients with Type 2 Diabetes May 04, 2021 Read More » Escient Pharmaceuticals Names Svetlana Makhni As Chief Financial Officer May 3, 2021 Read More » Synthekine Appoints Internationally Recognized Cancer Immunotherapy Leader Naiyer Rizvi, M.D., as Chief Medical Officer May 3, 2021 Read More » NGM Announces Nomination of Roger M. Perlmutter for Election to Its Board of Directors April 28, 2021 Read More » Revolution Medicines Announces Dosing of First Patient in Phase 1/1b Clinical Study of RMC-5552 in Patients with Advanced Solid Tumors April 21, 2021 Read More » « Previous Page1 Page2 Page3 Page4 Page5 Page6 Page7 Page8 Page9 Page10 Page11 Page12 Page13 Page14 Page15 Page16 Page17 Page18 Page19 Page20 Next »
NGM Bio Provides Business Highlights and Reports First Quarter 2021 Financial Results May 6, 2021 Read More »
ORIC Pharmaceuticals Reports First Quarter 2021 Financial Results and Operational Update May 6, 2021 Read More »
‘Changing the whole game of drug discovery’: Legendary R&D vet Roger Perlmutter leaps back into work as a biotech CEO May 5, 2021 Read More »
Eikon Therapeutics Closes $148 Million Series A Financing to Develop High-Throughput, Super-Resolution Microscopy for Drug Discovery May 5, 2021 Read More »
Perlmutter named CEO of Eikon, a biotech with $148M to apply Nobel-winning tech to undruggable targets May 5, 2021 Read More »
Carmot Therapeutics Announces Investigational New Drug (IND) Clearance for CT-868, a Dual GLP-1 and GIP Receptor Modulator for the Treatment of Overweight and Obese Patients with Type 2 Diabetes May 04, 2021 Read More »
Synthekine Appoints Internationally Recognized Cancer Immunotherapy Leader Naiyer Rizvi, M.D., as Chief Medical Officer May 3, 2021 Read More »
NGM Announces Nomination of Roger M. Perlmutter for Election to Its Board of Directors April 28, 2021 Read More »
Revolution Medicines Announces Dosing of First Patient in Phase 1/1b Clinical Study of RMC-5552 in Patients with Advanced Solid Tumors April 21, 2021 Read More »
